Botulinum neurotoxin type A resistance: An emerging problem
Mar 06, 2023•12 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
Botulinum neurotoxin A (BoNT-A), often referred to as ‘Botox’, is increasingly in cosmetic procedures. However, long-term use and high doses of BoNT-A may lead to immunoresistance, limiting its future therapeutic benefit.
A panel of experts including Dr Mary Dingley, Cosmetic Medicine Centre, Australia, is addressing this emerging issue. They offer guidance to practitioners and promote a culture of open communication with patients about BoNT-A risks, to empower individuals to make a fully informed decision.
Read more in Research Outreach
Read their original article : https://www.doi.org/10.1097/GOX.0000000000004407
For the best experience, listen in Metacast app for iOS or Android